News
-
-
PRESS RELEASE
Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways
Biomind Labs announced the decision to advance a Phase II clinical trial for BMND06, a novel compound with potential anti-inflammatory properties for treating obesity and neurological disorders